Veracyte Q1 EPS $0.52 on $139.1M Revenue Beats Forecast, Raises Guidance
Veracyte reported Q1 net income of $28.7 million, or $0.35 per share, with adjusted EPS of $0.52 on revenues of $139.1 million, surpassing analyst forecasts of $0.34 EPS and $130.5 million revenue. Management lifted full-year revenue guidance to $582–$592 million and analysts predict a 39% upside potential.
1. Strong Q1 Results
Veracyte posted first-quarter net income of $28.7 million, or $0.35 per share, and adjusted earnings of $0.52 per share on revenues of $139.1 million. Both adjusted EPS and revenue surpassed analysts’ forecasts of $0.34 per share and $130.5 million, respectively.
2. Raised Revenue Guidance
Management narrowed full-year revenue expectations to a range of $582 million to $592 million, citing continued volume growth in its Decipher and Afirma diagnostic platforms. The updated outlook reflects stronger-than-expected demand and improved profitability trends.
3. Bullish Analyst Price Targets
Analysts have set average price targets implying a potential 39% upside, driven by upward revisions in earnings estimates and the company’s expanding clinical evidence. The positive sentiment underscores confidence in sustained revenue growth and margin improvement.